clinical trial · NCT07011745
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Bristol-Myers Squibb·phase3·recruiting·n = 352
Alzheimer DiseaseXanomeline/Trospium Chloride CapsuleXanomeline Enteric CapsulePlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
started
Jul 16, 2025
primary completion
Nov 3, 2028
completion
Nov 13, 2028
last updated
Apr 22, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol